They're all the same. In the spring, because we were coming to the end of flu season, because of the uncertainties about the development of resistance, universally it was felt that we wanted to use Tamiflu or Relenza for those with underlying risk conditions that put them at greater risk of severe disease. That was the recommendation: everybody had access to that. We did not release the joint stockpile for general use, because again we didn't want it to be used in ways that would promote resistance. Come the fall, it doesn't matter who you are, the necessity for treatment is the same. It doesn't matter whether you are a firefighter or a Wal-Mart greeter; access to the antivirals is the same and will be the same. So there should be no issues there, and if there are issues, then they'll be dealt with directly.
On August 12th, 2009. See this statement in context.